Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc. develops anticancer drugs. Its pipeline includes DFP-10917 in phase 1/2 trials in the United States and phase I in Japan for relapsed/refractory acute myeloid leukemia; DFP-14323 in phase III for lung cancer; DFP-17729 in phase I/II for solid cancer; DFP-11207, which has completed phase I for pancreatic cancer; DFP-14927 in phase I for hematologic cancer; and DFP-10825 in preclinical trials for gastric/ovarian cancer. Incorporated in 2010, the company is headquartered in Tokushima, Japan.